Adage Capital Partners
DAWN

Adage Capital Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Adage Capital Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-800,000
Closed -$10.1M – 866
2024
Q4 		$10.1M Sell
800,000
-100,000
-11% -$1.39M 0.02% 602
2024
Q3 		$12.5M Buy
+900,000
New +$12.8M 0.02% 570
2024
Q2 		– Sell
-159,000
Closed -$2.63M – 886
2024
Q1 		$2.63M Buy
159,000
+9,000
+6% +$135K 0.01% 761
2023
Q4 		$2.19M Sell
150,000
-886,599
-86% -$10.7M ﹤0.01% 738
2023
Q3 		$12.7M Sell
1,036,599
-1,405,901
-58% -$18.3M 0.03% 517
2023
Q2 		$29.2M Buy
2,442,500
+1,702,500
+230% +$22.2M 0.06% 309
2023
Q1 		$9.89M Sell
740,000
-2,560,000
-78% -$50M 0.02% 620
2022
Q4 		$71M Buy
3,300,000
+260,000
+9% +$5.33M 0.17% 148
2022
Q3 		$60.9M Buy
3,040,000
+293,175
+11% +$6.24M 0.15% 157
2022
Q2 		$49.2M Buy
2,746,825
+2,570,976
+1,462% +$26.5M 0.11% 193
2022
Q1 		$1.74M Buy
175,849
+65,849
+60% +$870K ﹤0.01% 907
2021
Q4 		$1.85M Buy
110,000
+20,000
+22% +$411K ﹤0.01% 875
2021
Q3 		$2.14M Buy
+90,000
New +$2.16M ﹤0.01% 892

Other funds holding DAWN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
ECM
Estuary Capital Management Wayzata, Minnesota $598M AUM 1.72% 1-Year Est. Return

Adage Capital Partners's DAWN Position: Q1 2025 in Review

Adage Capital Partners sold out of Day One Biopharmaceuticals (DAWN) in Q1 2025, closing a stake of 800,000 shares — an estimated $10.1M sold.

Adage Capital Partners first reported a position in DAWN in Q3 2021 and held it in 13 quarters. The position peaked at $71M in Q4 2022. 184 funds tracked by Wall St. Rank hold DAWN as of Q1 2025.

  • Adage Capital Partners reported no remaining Day One Biopharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Adage Capital Partners sold 800,000 Day One Biopharmaceuticals shares in Q1 2025, an estimated $10.1M.
  • Adage Capital Partners first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 13 quarters.
  • Adage Capital Partners's Day One Biopharmaceuticals position peaked at $71M in Q4 2022.
  • 184 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2025.

Based on Adage Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.